Outgoing ASH President, David A. Williams, MD, of the Dana-Farber/Boston Children’s Hospital, gives an overview of this year’s Annual Meeting of the American Society of Hematology.
Mikkael A. Sekeres, MD, of the Cleveland Clinic, discusses an additional analysis of a phase II study of azacitidine combined with lenalidomide or with vorinostat vs azacitidine monotherapy in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia (Abstract 908).
S. Vincent Rajkumar, MD, of the Mayo Clinic, summarizes his education session on the evolving diagnostic criteria for myeloma, which focused on smoldering disease and when it becomes an “open flame.”
James N. Kochenderfer, MD, of the National Cancer Institute, discusses a clinical trial of allogeneic T cells expressing an anti-CD19 chimeric antigen receptor, which caused remissions of B-cell cancers after stem cell transplant, without causing graft-vs-host disease (Abstract LBA1).
Ronald Go, MD, of the Mayo Clinic, discusses a study that used the National Cancer Data Base to determine the extent to which the number of non-Hodgkin lymphoma patients treated annually in a facility affects overall survival (Abstract 266).
Olivier Casasnovas, MD, of Hôpital Le Bocage, discusses in French a phase III study comparing an early PET-driven treatment de-escalation to a not PET-monitored strategy in patients with advanced Hodgkin lymphoma (Abstract 577).
